CClinicalTrials.gg
CompletedNCT02094287Updated Sep 18, 2015

Placebo Effect in the Treatment of Atopic Dermatitis

An interventional study of dimetindene and instruction in Atopic Dermatitis, sponsored by Margitta Worm. Completed at 2 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-09-18.

Sponsored by Margitta Worm · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study is initiated in the indication of atopic dermatitis to study the impact of placebo in the treatment of pruritus. Classical conditioning and expectation via instructions/anticipation maintain the effect of placebo.

02

Conditions studied

03

In context

Dermatitis, Atopic

1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.

This study's enrollment of 166 is above the median of 83 across 1,125 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Margitta Worm is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • SCORAD-Score \< 50 points
  • basic experimental pruritus >= 3 points on a numeric rating scale
  • no acute eczema on their forearms
  • no systemic treatments for skin diseases for at least four weeks
  • no topical treatment on their arms for at least two weeks

Exclusion criteria

Exclusion Criteria:

  • intake of antihistamines
  • pregnancy and lactation
  • serious dysfunctions of the liver, kidneys or thyroid
  • prostatic hyperplasia
  • patients with tumors, major cardiovascular diseases, immunosuppression
  • glaucoma
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    verum, instruction, conditioning

    This group received dimetindene and instructions about dimetindene and its effectiveness. One classical conditioning process with saline was applied during the skin prick test procedures.

    Drug: dimetindene · Behavioral: instruction · Other: conditioning

  • Experimental
    verum, instruction, no conditioning

    This group received dimetindene and instructions about dimetindene and its effectiveness. No conditioning process were applied

    Drug: dimetindene · Behavioral: instruction

  • Experimental
    placebo, instruction, conditioning

    This group received a placebo (saline) as intravenously administered substance. But instructions about receiving dimetindene and its effectiveness were given. One classical conditioning process was applied during the skin prick test procedures.

    Behavioral: instruction · Other: conditioning

  • Experimental
    verum, no instruction, no conditioning

    Dimetindene was covertly administered (unawareness of treatment). No instruction and no conditioning were given.

    Drug: dimetindene

Interventions

  • Drugdimetindene

    receiving either dimetindene or a placebo (saline) via infusion

  • Behavioralinstruction

    information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment

  • Otherconditioning

    classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.

    Also known as: learning experience

06

What researchers measure

Primary outcomes

  1. Comparison of the experimental pruritus intensity on a 10-point-rating scale between the groups

    The pruritus intensity is assessed at different time points during a time frame of 2 days. The results are compared between the groups.

    Time frame: assessed over a time frame of 2 days

Secondary outcomes

  1. Change of the severity of atopic dermatitis (SCORAD) and comparison between the groups

    Change of SCORAD is assessed on day 1 and day 2.

    Time frame: assessed over a time frame of 2 days

  2. Changes of Wheal sizes experimentally provoked by skin prick test.

    The changes of wheal sizes due to the administered intervention at different time point during a time frame of 2 day is assessed in square millimeters. The results are compared between the groups.

    Time frame: assessed over a time frame of 2 days

  3. Changes of clinical, atopic itch intensity on a 10-point-rating scale

    Changes of clinical itch intensity assessed on day 1 and day 2.

    Time frame: assessed over a time frame of 2 days

07

Study locations

2 sites
  • Charité - University Medicine Berlin
    Berlin, 10117, Germany
  • University of Hamburg
    Hamburg, 20146, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02094287
Lead sponsor
Margitta Worm
Collaborators
University of Hamburg-Eppendorf
Responsible party
Margitta Worm (Prof. Dr., Charite University, Berlin, Germany) — Sponsor-investigator
First posted
Mar 21, 2014
Start date
Sep 2010
Primary completion
Nov 2013
Completion
Feb 2015
Last update
Sep 18, 2015

Study contacts

Margitta Worm, Prof. Dr.
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion